Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × trilaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 8 Triple Negative Breast Neoplasms 6 Breast Neoplasms 6 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Pathologic Complete Response 1 Osteosarcoma 1 Neutropenia 1 Neoplasms 1 NSCLC 1 Myelosuppression 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

osimertinib 11 Pemetrexed 10 Carboplatin 10 aflutinib 8 Gefitinib 7 Drug Therapy 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Taixing People's Hospital

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡